Journal: NPJ breast cancer
This retrospective cohort study analyzed 119,430 breast cancer patients with type 2 diabetes using a national electronic health record database.
It found that compared to White patients, Asian, Black, and patients of other races were significantly less likely to receive glucagon-like peptide-1 receptor agonists (GLP-1RAs), even after controlling for overweight and obesity.
Given the benefits of GLP-1RAs in:
- Glycemic control
- Weight loss
- Cardiovascular protection
- Mortality reduction
—all factors crucial to breast cancer survivorship—these racial disparities highlight a critical need to improve equitable access to this therapy in survivorship care.